Biognosys is expanding its laboratory in the Bio-Technopark Schlieren-Zurich. The company will consequently have one of the largest high-end mass spectrometry laboratories worldwide. The lab will provide contract research services to global pharma.



Biognosys is investing in its headquarters in the Bio-Technopark Schlieren-Zurich. The spin-off from the Swiss Federal Institute of Technology in Zurich (ETH) plans to expand its facilities by 900 square meters with an additional office and laboratory. According to a press release, this will make it one of the largest high-end mass spectrometry laboratories worldwide.

Biognosys has developed technology based on high-resolution mass spectrometry, which enables unprecedented parallel quantification of thousands of proteins in a single experiment. This technology enables the company to offer contract research services to global pharma and biotech customers. The laboratory extension means Biognosys can provide industry-leading sample throughput and project turnaround times.

“With this expansion we are well prepared to drive the transition towards proteomics as a source of functional data next to genomics at a large scale,” explained Oliver Rinner, CEO of Biognosys.

In addition to this facility extension, Biognosys will develop its portfolio of software and reagent products for proteomics data analysis. These are powered by machine learning and artificial intelligence algorithms.

Contact us

Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?